Why Botanix Pharmaceuticals fell 53% despite encouraging Sofdra metrics

A softer-than-expected launch update for hyperhidrosis treatment Sofdra sent Botanix Pharmaceuticals down 53%, even as underlying prescriber and refill data looked strong.

1 Oct 2025 · 5 min read

Dermatology company Botanix Pharmaceuticals saw its share price fall 53% in a single month after a softer-than-expected launch update for its FDA-approved hyperhidrosis treatment, Sofdra. SG Hiscock & Company's July 2025 Monthly Report detailed new scripts running around 16% below market expectations, compounded by confusing messaging around patient numbers and higher cash burn in the quarter.

A launch miss on numbers, not necessarily on product quality

Salter Brothers' August 2025 Monthly Report detailed the specific shortfall: approximately 17,000 total prescriptions sold with net revenue of $5.0 million for the second half of the 2025 calendar year, below both internal and consensus forecasts, driven by lower script volumes and a softer net price. The report noted encouraging underlying metrics nonetheless, including strong refill rates of 3.4 fills for February starters versus an industry average of around 2 per year, and high patient adherence of approximately 79%, with the company providing its first gross-to-net guidance of 30-40%, broadly in line with long-term assumptions.

We view developments as being negative, partly for the slow cashflow ramp, but largely for what we feel has been the poorly handled market expectations by management.

— Monash Investors, Monthly Report, July 2025

Monash Investors' July 2025 report was pointed about where responsibility for the reaction lay, suggesting the issue reflected either poor form from management, a lack of appreciation for the true sales and cash flow ramp, or a genuinely greater degree of uncertainty around ultimate commercial success, while noting prior profit-taking at higher levels had helped the fund contain its exposure through the fall. SG Hiscock & Company's own July 2025 report took a more constructive view, arguing the share price reaction was driven largely by a mismatch in expectations rather than a change in the fundamental opportunity, with Sofdra prescriptions increasing materially and unique prescribers more than doubling.

What managers are watching next

Salter Brothers confirmed the company remained well funded with $64.9 million in cash as at 30 June 2025 and access to a further $15.3 million in undrawn debt, enough to fund operations through to profitability. With Lennox Capital Partners' October 2025 Presentation describing itself as keeping an eye on the stock from the bench after initially being very excited about the product, the key question for managers who retained positions is whether the encouraging refill and adherence metrics translate into a scripts recovery that restores confidence in the commercial trajectory.